Ignite Creation Date:
2025-12-25 @ 2:28 AM
Ignite Modification Date:
2025-12-27 @ 7:04 AM
Study NCT ID:
NCT05635734
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-11-18
First Post:
2022-11-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
Sponsor:
Cantex Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-05
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2022-11-23
First Submit QC Date:
None
Study First Post Date:
2022-12-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-14
Last Update Post Date:
2024-11-18
Last Update Post Date Type:
ACTUAL